242
· DOS Abstracts
Coagulant preventing drugs in patients with hip
fractures
Bjarke Viberg, Lasse Enkebølle Rasmussen
Dept. of Orthopaedic Surgery and Traumatology, Odense University Hospital
Background:
Anticoagulants and antiplatelets are widely used in the elderly
population and new drugs have emerged on the market. Hip fracture patients
often needs major surgery and the national guidelines recommend surgery
within 24 hours. Some of the coagulant preventing drugs may increase periop-
erative bleeding and surgical delay.
Purpose / Aim of Study:
To estimate how many elderly hip fracture patients
are treated with anticoagulants or antiplatelets.
Materials and Methods:
Data on all hip fractures in patients above 60 years
old undergoing surgery at Funen were retrieved for the period of 2008 to
2013. The first hip fracture for each patient within the study period was eligible
for analysis. Patient id was matched in the prescription database for drug use,
which was assessed as the proportion of patients having filled a prescription for
an anticoagulant or antiplatelet drug within 120 days prior to their surgery. The
following drugs were included: (1) vitamin K antagonists (VKA), (2) new oral
anticoagulants (NOAC), (3) ADP-receptor blockers, (4) dipyridamole and (5)
low-dose acetylsalicylic acid (ASA).
Findings / Results:
4,253 patients were included in the study. 70.6% were
female and the median age were 83.2 (IQR 60.1-88.4). Over the entire study
period, 40.3% (n=1,716) had filled a prescription for one or more anticoagu-
lants or antiplatelets. 11.4% had filled more than one drug class. 31.6% had
filled a prescription for ASA, 10.2% for dipyridamole, 6.1% for VKA, 3.7% for
ADP-receptor blockers, and 0.4% for NOACs. Over the study period, use of VKA
and ADP-receptor blockers increased from 4.7% to 8.2% and 2.4% to 6.9% re-
spectively. NOAC was registered in 2011 and the use of NOAC increased from
zero to 1.8%
Conclusions:
Use of coagulant preventing drugs are common among patients
with hip fractures.
189.
